Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

Company Overview

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $64.97 to $64.97
• 50-Day Range: $64.37 to $64.97
• 52-Week Range: $8.33 to $65.00
• Volume: 2 shs
• Average Volume: 1.92 million shs
• Market Capitalization: $4.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.00
• Consensus Rating: Hold

ALPN Stock Analysis - Frequently Asked Questions

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.56. The biotechnology company had revenue of $8.52 million for the quarter, compared to analysts' expectations of $22.30 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 14.86% and a negative net margin of 65.17%.

What other stocks do shareholders of Alpine Immune Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpine Immune Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ALPN
• CIK: 1626199
• Web: www.alpineimmunesciences.com
• Phone: (206) 788-4545
• Fax: 303-440-8399
• Employees: 142
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $65.00
• High Stock Price Target: $65.00
• Low Stock Price Target: $65.00
• Potential Upside/Downside: +0.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-32,180,000.00
• Net Margins: -65.17%
• Pretax Margin: -64.99%
• Return on Equity: -14.86%
• Return on Assets: -11.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.56
• Quick Ratio: 9.56

Sales & Book Value

• Annual Sales: $56.52 million
• Price / Sales: 78.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.85 per share
• Price / Book: 13.40

Miscellaneous

• Outstanding Shares: 68,598,000
• Free Float: 39,581,000
• Market Cap: $4.46 billion
• Optionable: Optionable
• Beta: 0.97